Clinical Trials Logo
  1. Home
  2. Malaria
  3. NCT05535465
  4. Details
NCT05535465 Clinical Trial

Malaria Control : Improving Access to Prevention, Diagnostic and Care for Vulnerable Rural Communities

Malaria Clinical Trial

— REACT-2  

Official title:
Malaria Control : Improving Access to Prevention, Diagnostic and Care for Vulnerable Rural Communities

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05535465
Other study ID # IRD-2-002
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 1, 2021
Est. completion date September 1, 2024

Study information
Verified date September 2022
Source Institut de Recherche pour le Developpement
Contact Cédric Pennetier, PhD
Phone 0022656080455
Email cedric.pennetier@ird.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In the REACT 2 project, a consortium proposes to study in Burkina Faso and Côte d'Ivoire, the impact of a public health intervention in rural communities in order to improve access to malaria therapeutic and preventive arsenal for vulnerable populations (i.e. children, adolescents and pregnant women). The intervention relies on the implementation of mobile health workers to support community health workers.

Recruitment information / eligibility
Status Recruiting
Enrollment 7500
Est. completion date September 1, 2024
Est. primary completion date February 1, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Months and older
Eligibility Inclusion Criteria: - global population Exclusion Criteria: - absence of informed consent

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Public health intervention
additional trained mobile health workers are hired to support and supervise the activities of community health workers

Locations
Country Name City State
Burkina Faso IRSS Bobo-Dioulasso Houet
Côte D'Ivoire IPR Bouaké

Sponsors (4)
Lead Sponsor Collaborator
Institut de Recherche pour le Developpement Expertise France, Institut de Recherche en Sciences de la Sante, Burkina Faso, Institut Pierre Richet

Countries where clinical trial is conducted

Burkina Faso,  Côte D'Ivoire, 

Outcome
Type Measure Description Time frame Safety issue
Primary Difference of malaria incidence between control and intervention arms Incidence will be calculated as the number of malaria cases detected during the cross-sectionnal surveys relative to the population size Day 0 (cross-sectional survey)
Secondary Difference of malaria prevalence between control and intervention arms Prevalence will be calculated as the proportion of participants with malaria infection (i.e. positive blood smears) detected during the cross-sectionnal surveys Day 0 (cross-sectional survey)
See also
  Status Clinical Trial Phase
Completed NCT04601714 - Baseline Cohort Malaria Morbidity Study
Withdrawn NCT04020653 - A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria Phase 2
Terminated NCT04368910 - Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria Phase 3
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02544048 - Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Active, not recruiting NCT04704674 - Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
Completed NCT03276962 - Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age Phase 2
Completed NCT04966871 - Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults Phase 1
Completed NCT00289185 - Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Phase 2
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Active, not recruiting NCT06153862 - Africa Ready Malaria Screening N/A
Completed NCT04545905 - Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
Recruiting NCT06278181 - Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Withdrawn NCT02793414 - Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
Withdrawn NCT02793388 - A Trial on Supervised Primaquine Use in Ethiopia Phase 4
Completed NCT02793622 - Prevention of Malaria in HIV-uninfected Pregnant Women and Infants Phase 3
Completed NCT02605720 - Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns Phase 3